Drugs / Dipraglurant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02447640 | Apr 2015 → Dec 2017 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05027997 | Oct 2021 → Oct 2022 | benign essential blepharospasm | Addex Pharma S.A. | Completed | No outcome recorded |
| Phase 2 | NCT01336088 | Apr 2011 → Feb 2012 | Parkinson disease | Addex Pharma S.A. | Completed | Met primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05116813 | Oct 2021 → Jun 2022 | Parkinson disease, drug-induced dyskinesia, movement disorder | Addex Pharma S.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04857359 | Aug 2021 → Jun 2022 | Parkinson disease, drug-induced dyskinesia, movement disorder | Addex Pharma S.A. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 23
| Date | Issuer | Release |
|---|---|---|
| 2023-09-04 | Addex Pharma S.A. | Results Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain addextherapeutics.com ↗
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions |
| 2023-04-04 | Addex Pharma S.A. | Results Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease addextherapeutics.com ↗
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that dipraglurant could have beneficial effects on non-motor symptoms (NMS) experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias. |
| 2022-05-27 | Addex Pharma S.A. | Results Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study addextherapeutics.com ↗
Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives. |
| 2021-05-17 | Addex Pharma S.A. | Results Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia addextherapeutics.com ↗ |
| 2016-06-02 | Addex Pharma S.A. | Results Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society addextherapeutics.com ↗ |
| 2016-04-11 | Addex Pharma S.A. | Results Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today the results of the mGlu5 receptor occupancy study with dipraglurant in healthy volunteers. |
| 2016-01-11 | Addex Pharma S.A. | Results Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that dipraglurant shows a statistically significant anti-dyskinetic effect, over the total treatment duration of 28 days, following additional analysis of the previously reported data from the Parkinson’s disease levodopa-induced dyskinesia Phase II proof of concept (POC) clinical trial. |
| 2016-01-04 | Addex Pharma S.A. | Regulatory Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to dipraglurant for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). |
| 2015-12-17 | Addex Pharma S.A. | Results Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today positive interim data for dipraglurant in an mGlu5 receptor occupancy study in healthy volunteers. |
| 2015-08-14 | Addex Pharma S.A. | Results Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease addextherapeutics.com ↗
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that its lead compound dipraglurant, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) demonstrated robust efficacy in multiple preclinical models of anxiety and depression. |
| 2015-05-29 | Addex Pharma S.A. | Results Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia addextherapeutics.com ↗ |
| 2013-09-04 | Addex Pharma S.A. | Results Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 addextherapeutics.com ↗
Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 |
| 2013-05-02 | Addex Pharma S.A. | Results Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study addextherapeutics.com ↗
The study demonstrated the correlation between the plasma concentration of dipraglurant and occupancy of dipraglurant on mGlu5 receptors in the brain. |
| 2013-04-22 | Addex Pharma S.A. | Regulatory Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant addextherapeutics.com ↗
Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that the European Patent Office granted Addex a broad composition of matter patent (European patent, EP 1 765 795) covering dipraglurant and other mGlu5 negative allosteric modulators (NAM). |
| 2013-04-18 | Addex Pharma S.A. | Results Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) addextherapeutics.com ↗
Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) |
| 2013-03-21 | Addex Pharma S.A. | Results Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN) addextherapeutics.com ↗
We believe the successful completion of the Phase 2a study showed significant promise that dipraglurant has the potential to change the way these patients are treated as well as their quality of life, |
| 2013-01-29 | Addex Pharma S.A. | Results Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia addextherapeutics.com ↗
Dipraglurant demonstrated a robust and dose-dependent reduction in severity of a dystonia-like attack, induced by caffeine in the tottering mouse model. |
| 2012-06-18 | Addex Pharma S.A. | Results Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society’s International Congress addextherapeutics.com ↗
The data show that dipraglurant met the primary objective of the study by exhibiting a good safety and tolerability profile. |
| 2012-03-21 | Addex Pharma S.A. | Results Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) addextherapeutics.com ↗
Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today positive top line data from a Phase IIa clinical study of dipraglurant in Parkinson's disease (PD) patients suffering from debilitating levodopa-induced dyskinesia (LID). |
| 2010-06-15 | Addex Pharma S.A. | Results Addex’s ADX48621 Effective in Preclinical Parkinson’s Disease Studies addextherapeutics.com ↗ |
| 2009-11-24 | Addex Pharma S.A. | Results Addex ADX48621 Positive Primate Parkinson’s Data addextherapeutics.com ↗
Addex Pharmaceuticals (SWX:ADXN), the allosteric modulation company, announced today that in a non-human primate model of Parkinson’s disease (PD) levodopa induced dyskinesia (LID), ADX48621 statistically and significantly inhibited LID. |
| 2009-01-28 | Addex Pharma S.A. | Results Addex Successfully Completes ADX48621 Phase I Program addextherapeutics.com ↗
The studies showed that ADX48621, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) in development for Parkinson’s disease levodopa induced dyskinesia (PD-LID), is safe and well-tolerated in healthy volunteers, including those over 50 years old. |
| 2008-10-15 | Addex Pharma S.A. | Results Addex Parkinson’s Product Progressing in Early Clinical Trials addextherapeutics.com ↗
The modified release formulation achieved the predefined pharmacokinetic criteria required to continue into Part Two. |
All press releases naming this drug 38 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dipraglurant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857359 ↗ |
| Known as | ADX48621 | “Dipraglurant (ADX48621)” NCT05116813 ↗ |
| Action | Inhibit | “negative allosteric modulator” NCT02447640 ↗ |
| Modality | Small molecule | — CHEMBL2346738 ↗ |
| Route | Oral | “oral dosing of ADX48621” NCT02447640 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 modulator” CHEMBL2346738 ↗ |